Philips demonstrates innovation power, topping European Patent Office Medtech filings in 2024
25 Mars 2025 - 9:15AM
UK Regulatory
Philips demonstrates innovation power, topping European Patent
Office Medtech filings in 2024
March 25, 2025
Amsterdam, the Netherlands – Royal
Philips (NYSE: PHG, AEX: PHIA), a global leader in health
technology, today announced that in 2024 it was the leading
applicant in the field of medical technology at the European Patent
Office (EPO), filing 594 Medtech patent applications. This
achievement underscores the company's ongoing dedication to
transforming healthcare delivery by integrating informatics and AI
to improve workflows, enhance the quality of care, and lower costs
of care per patient.
The innovations by Philips, which can boast 134 years of innovation
history with its research and development programs around the
globe, improved the health and well-being of nearly 2 billion
people in 2024, keeping it on track towards its target of 2.5
billion lives improved in 2030.
Roy Jakobs, CEO of Royal Philips said: "For more than 130 years,
Philips has been at the forefront of innovations improving people’s
lives. The 2024 European patent rankings show how we continue to
innovate in the hospital and the home – helping to deliver better
care for more people. To continue driving greater impact, we have
shifted our innovation closer to customers. We want to help
healthcare professionals improve patient care and empower people
everywhere to take care of their health and well-being.”
As informatics and AI increasingly create value for
healthcare both at the hospital as well as at home, approximately
half of the company’s R&D investments are focused on these
technologies.
Some of the informatics and AI-powered innovations that Philips
launched in 2024 include:
- The new Azurion
image-guided therapy system with advanced informatics to enhance
minimally invasive diagnosis and treatment of stroke and other
neurovascular patients.
- FDA-cleared AI tools
integrated into the EPIQ CVx and Affiniti CVx ultrasound system to
advance cardiovascular imaging and increase automation and
productivity, reinforcing Philips’ #1 global position in
cardiovascular ultrasound.
- The new Philips
Spectral CT 7500 RT, enabling personalized radiation therapy
planning to deliver better care to more cancer patients.
- FDA approval for the
LumiGuide Navigation Wire, which uses fiber optic technology to
reduce radiation for both patients and physicians during minimally
invasive surgery.
In total, Philips contributed 1,231 European patent applications
across various domains, the most of any Dutch company and
continuing the company’s legacy as one of the top applicants since
the EPO started publishing the rankings in 2004.
Further illustrating Philips’ innovation leadership is the
company’s recent inclusion in the Clarivate Top 100 Global
Innovators 2025, marking the company’s 12th consecutive inclusion
in this major assessment of global innovators.
Philips invested approximately EUR 1.7 billion in research and
development in 2024 to help drive better care for more people. At
more than 9% of sales, this is well above the industry average. The
company's extensive intellectual property portfolio includes 50,500
patent rights, 30,500 trademarks, 150,000 design rights, and 3,200
domain names.
For further information, please
contact:
Elco van Groningen
Philips Global External Relations
Tel.: +31 6 8103 9584
E-mail: media@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology
company focused on improving people’s health and well-being through
meaningful innovation. Philips’ patient- and people-centric
innovation leverages advanced technology and deep clinical and
consumer insights to deliver personal health solutions for
consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2024 sales of EUR 18 billion and employs approximately
67,800 employees with sales and services in more than 100
countries. News about Philips can be found
at www.philips.com/newscenter.
- AI-enabled cardiovascular ultrasound platform
- AI-enabled cardiovascular ultrasound platform
- Lumiguide navigation wire
- Azurion
- Azurion with 3d treatment view
- Spectral CT7500 for RT
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Juin 2025 à Juil 2025
Koninklijke Philips NV (EU:PHIA)
Graphique Historique de l'Action
De Juil 2024 à Juil 2025